Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma

• Main Authors: Zhong-Kun Xia (Author), Wei Wang (Author), Jian-Ge Qiu (Author), Xi-Nan Shi (Author), Hong-Jian Li (Author), Rong Chen (Author), Kun-Bin Ke (Author), Chao Dong (Author), Ying Zhu (Author), Shi-Guo Wu (Author), Rong-Ping Zhang (Author), Zhuo-Ran Meng (Author), Hui Zhao (Author), Peng Gu (Author), Kwong-Sak Leung (Author), Man-Hon Wong (Author), Xiao-Dong Liu (Author), Feng-Mei Zhou (Author), Jian-Ying Zhang (Author), Ya-Ting Yao (Author), Si-Jia Wang (Author), Chun-Yang Zhang (Author), Yan-Ru Qin (Author), Marie Chia-mi Lin (Author), Bing-Hua Jiang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Hepatocellular carcinoma (HCC) is a lethal malignancy lacking effective treatment. The Cyclin-dependent kinases 4/6 (CDK4/6) and PI3K/AKT signal pathways play pivotal roles in carcinogenesis and are promising therapeutic targets for HCC. Here we identified a new CDK4/6 and PI3K/AKT multi...